Balanced Green Primary Logo Medium 1000px.png
Revolution Medicines Reports Fourth Quarter and Full Year 2024 Financial Results and Update on Corporate Progress
26. Februar 2025 16:02 ET | Revolution Medicines, Inc.
Company anticipates substantially completing enrollment this year in ongoing Phase 3 RASolute 302 trial of daraxonrasib in previously treated metastatic pancreatic cancer to enable expected data...
Balanced Green Primary Logo Medium 1000px.png
Revolution Medicines to Participate in March 2025 Investor Conferences
24. Februar 2025 16:05 ET | Revolution Medicines, Inc.
REDWOOD CITY, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing novel targeted therapies for patients with...
Balanced Green Primary Logo Medium 1000px.png
Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2024 After Market Close on February 26, 2025
19. Februar 2025 16:05 ET | Revolution Medicines, Inc.
REDWOOD CITY, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing novel targeted therapies for patients with...
Balanced Green Primary Logo Medium 1000px.png
Revolution Medicines to Participate in the Guggenheim Securities SMID Cap Biotech Conference
29. Januar 2025 16:05 ET | Revolution Medicines, Inc.
REDWOOD CITY, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for patients with...
Balanced Green Primary Logo Medium 1000px.png
Revolution Medicines to Present at 43rd Annual J.P. Morgan Healthcare Conference
06. Januar 2025 16:05 ET | Revolution Medicines, Inc.
REDWOOD CITY, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for patients with...
Balanced Green Primary Logo Medium 1000px.png
Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares
05. Dezember 2024 16:05 ET | Revolution Medicines, Inc.
REDWOOD CITY, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted...
Balanced Green Primary Logo Medium 1000px.png
Revolution Medicines Announces Pricing of Upsized $750.0 Million Public Offering of Common Stock and Pre-Funded Warrants
03. Dezember 2024 22:38 ET | Revolution Medicines, Inc.
REDWOOD CITY, Calif., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted...
Balanced Green Primary Logo Medium 1000px.png
Revolution Medicines Announces Commencement of Public Offering of Common Stock
02. Dezember 2024 16:31 ET | Revolution Medicines, Inc.
REDWOOD CITY, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted...
Revolution Medicines.jpg
Revolution Medicines Provides Clinical Updates from its RAS(ON) Inhibitor Portfolio
02. Dezember 2024 07:30 ET | Revolution Medicines, Inc.
Compelling Phase 1/1b update on RMC-6236 monotherapy in second-line metastatic pancreatic ductal adenocarcinoma supports ongoing Phase 3 RASolute 302 clinical trial Phase 1/1b proof-of-concept for...
Revolution Medicines.jpg
Revolution Medicines to Host RAS(ON) Inhibitor Clinical Update Webcast on December 2, 2024
27. November 2024 16:05 ET | Revolution Medicines, Inc.
REDWOOD CITY, Calif., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted...